Globus Medical (GMED) Competitors

Globus Medical (NYSE:GMED) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Is GMED or IDXX more profitable?

IDEXX Laboratories has a net margin of 22.78% compared to Globus Medical's net margin of 4.09%. IDEXX Laboratories' return on equity of 55.82% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	4.09%	10.83%	8.63%
IDEXX Laboratories	22.78%	55.82%	26.48%

Do institutionals and insiders believe in GMED or IDXX?

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 18.5% of Globus Medical shares are held by company insiders. Comparatively, 2.1% of IDEXX Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the media prefer GMED or IDXX?

In the previous week, IDEXX Laboratories had 8 more articles in the media than Globus Medical. MarketBeat recorded 25 mentions for IDEXX Laboratories and 17 mentions for Globus Medical. IDEXX Laboratories' average media sentiment score of 1.57 beat Globus Medical's score of 0.65 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	10 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEXX Laboratories	22 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Does the MarketBeat Community believe in GMED or IDXX?

Globus Medical received 36 more outperform votes than IDEXX Laboratories when rated by MarketBeat users. However, 71.89% of users gave IDEXX Laboratories an outperform vote while only 67.41% of users gave Globus Medical an outperform vote.

Company	Underperform	Outperform
Globus Medical	Outperform Votes 573 67.41%	Underperform Votes 277 32.59%
IDEXX Laboratories	Outperform Votes 537 71.89%	Underperform Votes 210 28.11%

Do analysts recommend GMED or IDXX?

Globus Medical currently has a consensus target price of $97.09, suggesting a potential upside of 26.67%. IDEXX Laboratories has a consensus target price of $533.75, suggesting a potential upside of 27.80%. Given IDEXX Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe IDEXX Laboratories is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
IDEXX Laboratories	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.80

Which has preferable earnings and valuation, GMED or IDXX?

IDEXX Laboratories has higher revenue and earnings than Globus Medical. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.52B	4.18	$122.87M	$0.75	102.20
IDEXX Laboratories	$3.90B	8.69	$887.87M	$10.67	39.14

Which has more risk & volatility, GMED or IDXX?

Globus Medical has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Summary

IDEXX Laboratories beats Globus Medical on 14 of the 19 factors compared between the two stocks.